Enabling Unbounded Possibilities - RSD

WuXi RSD Leadership:

Steve Yang

WuXi RSD Business Development:

US: Declan Ryan

EU: Dave Madge

Israel: Dana Yarden

Japan: Yan Zhu

Korea: Suk Young Cho

China: Marcher Xu

Enabling Unbounded Possibilities

[email protected] [email protected]

[email protected]

[email protected]

[email protected],

[email protected]

[email protected]

The WuXi AppTec Research Service Division (RSD) aims at

providing superior support to our partners and promoting

efficiency and collaboration between WuXi’s business

units. RSD combines WuXi’s capability and technology

platform in chemistry, biology, oncology, and immunology

to provide open access and integrated service for drug

discovery and research. The services include in the new

RSD are the International Discovery Service Unit (IDSU),

the Chemistry Service Unit (CSU), the Oncology-

Immunology Unit, the Core Analytical Services Unit (CAS),

the Biology Unit (which includes HTS, in vitro screening,

infectious diseases, neurosciences, fibrosis, cardiovascular

and metabolic diseases), Crelux and newly acquired HD

Biosciences (HDB). This new integration will provide closer

points of contacts for our partners and discovery teams,

streamline the exceptional services offered across our

platform, and enhance efficiency and productivity to drug

discovery. We will focus on boosting our scientific

capabilities and leading technology development to

maintain WuXi’s industry leading position in technology

and research service. We aim to provide outstanding

service to our existing partners and to our broader

discovery community!

Steve Yang, Ph.D.

Chief Business Officer EVP & Head of RSD

International Discovery Service Unit

(IDSU)

Med. Chem. design solutions

Project management

Deliver preclinical candidates

Chemistry Service Unit (CSU)

Speed and quality syntheses

Shorten synthesis cycle time

Core Analytical Services Unit

(CAS)

Analytical testing and release

High throughput purification

SFC large scale chiral

separation

Impurity isolation and

identification

Natural products

Biology Unit

HTS and novel libraries

In vitro screening

platform

General pharmacology

Infectious disease

platform

Specialty models

including NASH

Crelux

High quality protein

production

Fragment screening

and biophysical hit

finding

X-ray crystallography

Oncology-Immunology Unit

CRISPR, targeted oncology

(PDX), immuno-oncology,

translational oncology

Immunology Center

Autoimmune and

inflammatory diseases

Comprehensive R&D enabling capability

RSD integrated platforms enable anyone or any company to discover and develop new drugs and products benefit to

patients. RSD services deliver extraordinary performance and an unwavering focus on customer satisfaction.

Target validation, CRISPR

Protein production

HTS, FBDD


Biophysical analytics

CADD

In vitro efficacy & MoA

In vivo efficacy

PK/PD analysis

In vitro SAR support

Selectivity panel

Cell panel

In vivo target engagement

In vivo pharmacology

hERG, other safety profiling

services

Ligand binding

Receptor profiling

Additional in vitro and in vivo characterization

PDX

Tumor TILs

Biomarkers

CAP-certified FACS, pathology,

molecular testing

R&D Biological Science Chemistry

Reference compounds

Arrays, Libraries, DELs

Unique scaffolds, building blocks

DNA-Encoded Libraries

Customized screening decks

SAR generation

Molecule design

Building blocks

Optimization of hits and

leads

Data interpretation

Candidate selection

Scale up of candidates for

preclinical studies

Synthetic optimization of

candidates

Metabolic and impurity

identification synthesis

Hit-to-lead

Lead

Optimization

Pre-clinical

Target-to-hit

Clinical I - III

Commercial

HD Biosciences (HDB)

Biology-focused

preclinical drug

discovery

Drug target validation

HTS, H-T-L and LO

program support

Efficacy PK/PD,

disease models

IDSU

Oncology

Immunology

CSU CAS

Biology Crelux HDB

Enabling Unbounded PossibilitiesEnabling Unbounded Possibilities

A number of historical milestones characterize RSD’s

journey from regional individual testing services to

integrated platforms and massive capacity that enable us

to provide outstanding and cost-effective services to help

our global clients tackle challenges in their drug discovery

process. Throughout the past decade, we have introduced

new testing technologies, animal models, libraries and

other chemistry and biology services through a steady

flow of innovations, expansions and acquisitions.

A steady flow of innovations and portfolio expansions

Benefits of Partnering with WuXi AppTec RSD

■ Track record of leadership and excellence in contract research

■ A broad and integrated portfolio of discovery services and seamless transition development services

■ >5,000 scientists across integrated chemistry and biology platform

■ Fast turnaround, comprehensive services, cost-effective solutions and quality results

■ Global footprint with operations in North America, Asia and Europe

■ Established stringent policies and procedures for IP protection

Leadership and excellence in contract research

AAALAC accredited

SPF animal facility

Acquired Crelux

GLP-certified

hERG testing

Scale-up facility

for peptide synthesis

Launched

OncoWuXi database

Immunology Core

Supported delivery

of >60 preclinical drug

candidates

Novel technologies -

CRISPR, PDX, & CDX

Acquired HD

Biosciences


The Chemistry Service Unit (CSU) is led by an experienced

scientific leadership team staffed with over 1,300 synthetic

and analytical/purification chemists. Services by CSU range

from custom synthesis of client-directed molecules and

libraries to WuXi designed templates. Our focus on

technology and continued innovation allows us to offer

specialized services in peptides, nucleosides, fluorine

chemistry and natural products, all led by experts of the

respective fields.

Synthesis with speed and quality

WuXi-designed templates/template libraries.

Extensive access to reagents and components through

WuXi LabNetwork.

Compound collection management including storage,

registration, distribution, etc.

Impurity isolation, identification and structure

assignment/confirmation.

Natural product extracts or purified natural product

sourcing, purifications, QA/QC and structure elucidation.

Snapshot of Accomplishments

>17 years of experience in route design and synthesis

>1,000 clients worldwide

>3 million compounds delivered, >20,000 each year

>25,000 reagents plus 8,000+ novel building blocks in

stock

>95% on-time delivery rate and short cycle time

20-30% client synthetic routes re-designed by CSU

CSU Services

Synthetic

chemistryCatalog

reagents

Analytical

services

Peptide

services

Building block

synthesis

Library synthesis

Custom synthesis

Scale up synthesis

Route scouting

Discovery-process

chemistry (DPC)

Templates

Reagent service

Compound

management

Chiral separations

Impurity analysis

Natural products

Non-GMP

peptide synthesis

GMP facility in

2017

CSU Service

Capabilities

Support for early-stage

research programs

Rapid scale-up for late-

stage needs

Discovery process chemistry

(DPC)

Combination of strong

discovery chemistry

experience

Strong route scouting

capability

Catalog

>3,000 templates developed

>14,000 unique scaffolds and

building blocks in stock

104K screening compounds

Library synthesis

Rapid production

Diverse chemistries

Discovery scale & rapid scale-up


Enables discovery stage of drug research

The International Discovery Service Unit (IDSU) is WuXi’s

solution to address our industry’s drug discovery

challenges through expertise in medicinal chemistry and

program management. We collaborate closely with our

international customers ranging from pharma and biotech

to academia to rapidly advance programs towards key

inflection points and milestones by leveraging

IDSU’s peer-recognized expertise and WuXi’s

integrated platform from hit identification to preclinical

candidate selection and beyond. With some of the

industry’s finest and most experienced medicinal

chemists at WuXi, we aspire to become the partner-of-

choice in externalized solutions to enable advancement

of programs in ways that are both smarter and faster.

Structural

Biology &

Computational

Synthetic

Chemistry

Safety Assessment

& Toxicology

ADME &

DMPK

In Vitro Biology

& In Vivo Pharmacology

Medicinal

Chemistry

Multiple biology screening

platforms

HTS, component collection

Electrophysiology

Biophysical characterization

Oncology, immuno-oncology,

immunology core, infectious

diseases, neuroscience & CV/MED

Translational models

Genomic Center (CLIA-certified)

Biomarkers

Rodents to NHPs

Discovery to IND-

enabling

Metabolite ID

Radiolabeled studies

>2,700 chemists

Discovery to candidate

selection & scale-up

Radiolabel synthesis

Protein crystallography

FBDD, SBDD

Modeling &

Chemoinformatics

Non-GLP and GLP

Toxicokinetics &

bioanalytical

Pathology

Leveraging WuXi Integrated Discovery Capability

Target

to

hit

Hit

to

leadPhase I Phase IIIPhase II

Submission

& launch

Lead

optimizationPreclinical


>113,000 compounds delivered in

2017

>190 clients globally and >80%

from biotech and non-profit

organizations

34 publications in 2017

74 patent applications with WuXi

inventors

27 preclinical candidates (PCCs)

delivered in 2017

1st FDA-approved drug from

WuXi integrated platform

Partnering with IDSU

Collaborative. Having delivered 27 preclinical candidates in 2017 for our partners, we understand the unique challenges

and needs of each program. We work closely with partners to establish strategy, customize resources and guide project

execution to deliver on goals.

China Platform PartnerWuXi’s IDSU Team

Efficient. We provide our customers with access to WuXi’s best-in-class, fully integrated drug discovery and development

platform to seamlessly progress programs from target through to preclinical candidate selection and beyond.

Execution of

HTS & chemistry

in vitro & in vivo biology

DMPK & formulation

safety assessment

Medicinal chemistry

project execution

program management

Disease biology

target of interest

in-house expertise


Provide high quality integrated analytical services in a rapid & cost saving manner

The Core Analytical Services Unit (CAS) is led by a

dedicated and knowledgeable team with extensive

experience. Our focus on technology and continued

innovation allows us to offer specialized services in chiral

separation, high-throughput purification, physiochemical

property determination, and impurity isolation and

identification to our clients, and to meet their needs for

accurate and high quality data analysis on tight budget.

The CAS Unit is equipped with best-in-class automated

instruments to provide extensive GMP and non-GMP

conditions in both small and large scales.

SFC and/or HPLC chiral separation (mg to multi kg)

Regulated Analytical Research Services (ARS) for Drug

Development

High-throughput purification (500,000-700,000 compounds

annually)

Structure confirmation/elucidation (HRMS, 1D/2D NMR)

Physicochemical property determination (pKa, LogP/LogD,

thermodynamic and kinetic solubility, concentration)

Natural products extraction, purification, structure

identification and quality analysis

Isolation and structure elucidation for impurities of

regulatory starting materials, intermediates, APIs and drug

products.

Capability to purify /

characterize 500,000

compounds

MS and UV triggered Prep

HPLC fraction collection

Standard LC-UV-ELSD-MS

platform for QC of isolated

compound

Physiochemical properties: pKa,

LogD/LogP, thermodynamic and

kinetic solubility, etc.

Structure confirmation/elucidation Drug substance services

Drug product services

Stability studies

Reference material

standardization

Impurity isolation and

structure elucidation

High purity single compound

as reference

Most major natural product

classes covered in CAS Library,

~16% novel . (Non-exclusive

basis )

Bioassay guided isolation

Quality analysis of crude or

enriched extracts

Large scale single compound

extraction and isolation.

Major Services

for Natural

Products

Chiral

Separation

Services

Regulated

Analytical

Research

Services

High-

throughput

Purification

Physiochemical

Property

Determination

SFC/HPLC chiral separation

Separation method

development

Milligram and multi-kg scale

separation

ee Determination

Pure enantiomer racemization

study

Isolation of impurities/by-

products

Process Chemistry

Discovery Chemistry

Core Analytical Services Unit (CAS)

Integrated Analytical Services

Dedicated to Provide Analytical, Purification and Structure Elucidation Services

CAS

Tianjin

WuhanShanghai

CHINA

Snapshot of Chiral Separation Accomplishments

■ 14 sets analytical SFC, two equipped with MS detector

■ 12 sets semi-preparative SFC (flow rate 70-80 ml/min) equipped

with 2.5cm and 3cm columns

■ 11 sets prep-SFC instruments (flow rate 200-350 ml/min) equipped

with 5cm columns

■ 130 sets semi-prep and prep-HPLC to purify samples from mg to

multi-kg scales

■ Centralized CO2 delivery system with two 2,000-liter tanks


End-to-end service and solution to enable cancer drug discovery

Part of the Oncology and Immunology Unit, WuXi

Oncology team works efficiently with partners to enable

cancer drug discovery through our leading oncology and

immuno-oncology service capabilities. We provide a wide

panel of in vivo tumor model systems including human

cancer cell line-derived xenograft (CDX) models, murine

syngeneic tumor models/humanized models, and patient-

derived xenograft (PDX) models with in-depth genomic

characterization. We have established a comprehensive

immune profiling platform including TILs analysis, IHC

and TCR repertoire to advance immune-oncology

discovery. Our CRISPR screening and surrogate

antibodies can offer target validation service. The

oncology topnotch team has extensive experience in

IND-enabling studies for both FDA and CFDA filing as

either standalone or integrated drug discovery

programs, plus clinical biomarker service to support

clinical trials.

Oncology Platforms

Services

Solutions

>340 scientists, 70% with

MS/PhD

AAALAC credited SPF

animal facility

>6,000 IVC-cages capacity in

SPF barrier

WuXi Oncology Capabilities

TI/TS LO/TS IND/TS Clinical/Beyond

Medicinal Chemistry Toxicology cGMP Biology

Biologics WuXi NextCODE CDx Analytics

DMPK Clinical Trial CMC Commercial

Enable

Oncology Platforms from Drug Discovery to Translational Science

Biomarker discovery

o 18-color FACS-based analysis &

sorting

o Pathology lab

o Multiplexed IHC

Clinical Biomarker Services

o IHC, FISH, DISH, FACS

o CAP accreditation and GCP

compliance

CRISPR library in vitro & in vivo screening

o 18,000 genes

o Customized library

KO/KI of target genes

In vitro cancer biology

Xenograft Models

o >180 cell- linederived xenograft

(CDX) models

o 27 orthotropic models

o >1,000 patient-derived

xenograft (PDX) models

o SOC and genomic profiling

o Pathology services

54 syngeneic models

o Validated with checkpoint

inhibitors

o Immune profiling capability

o Humanized models

CRISPR/Cas9

Discovery &

Clinical

Biomarkers

Immuno-

Oncology

Oncology

>1,500 tumor models

Full annotation

o >3,000 growth curves

o >2,800 histology images

o >250 SOC studies

o >800 WES, CNV, Microarray & RNAseq

OncoWuXi Database


Efficacy and MoA study to facilitate immunotherapy drug discovery

Part of the Oncology and Immunology Unit, WuXi

Immunology Center is built to provide a comprehensive

open platform for immunological service of preclinical and

clinical studies, and to facilitate immunotherapy drug

discovery in cancer, autoimmune and inflammatory

diseases. Led by a group of US and European trained

immunologists, the team primarily serves clients’ needs for

efficacy and in depth mechanism of action (MoA) studies

by utilizing our cancer immunology platform, autoimmune

& inflammatory animal models, and biomarker detection

services. Our pathology lab and flow cytometry lab are

equipped with best-in-class automated instruments and

set up to follow GCP compliance and CAP regulation.

Immunology Center Services

In Vivo ModelsIn Vitro/Ex Vivo

Immunology

Flow Cytometry

Core

Surface &

intracellular

markers

Pre-clinical &

clinical studies

GCP/CAP

compliance

Biomarker services

Histology Core

Autoimmune

diseases,

inflammatory

animal models

Cancer

immunology

platform

Cell-based

biomarkers (flow-

cytometry lab)

Lab with GCP

compliance & CAP

accreditation

Soluble biomarkers (ELISA, Luminex,

CBA, MSD)

Tissue-based biomarkers

(pathology lab)

Integrated

Immunology

Platform

Immunology Center Capability


■ >100 validated biomarkers

■ Laboratories with GCP compliance and CAP accreditation

■ Top flow cytometry service lab among CROs

■ Combination immunotherapy evaluation

IHC, FISH, DDISH

Pre-clinical &

clinical studies

GCP/CAP

compliance

Biomarker services

Immune cell

functions

Cytokines/

chemokines

Adoptive T cell

therapy

Adoptive T cell

therapy

Autoimmune &

inflammatory

diseases

Cancer

immunotherapy


An open access biology platform for global drug innovation

The Biology Unit offers plate-based screening services

including HTS, SAR screening support, compound

selectivity and early safety profiling, and cancer cell panel

profiling. In addition, we offer disease models and

therapeutic expertise in CNS and pain, infectious diseases,

cardiovascular diseases, metabolic disorders

fibrotic diseases. The 310+ membered team is

composed of 11% PhD, 54% MSc, and led by 14

seasoned scientific leaders with an average of 15

years of R&D experience in US, Canada, and UK.

>43,000 sq ft of Biology Labs, AAALAC-

accredited SPF animal facility

>250 global partners

>40 drug candidates delivered in 2008-2014

through integrated team effort

1st GLP-certified hERG testing; CAP-certified

molecular testing Lab (clinical virology)

Stand alone services

Integrated programs

HTS & novel screening libraries

Broad therapeutic area coverage

In vitro & in vivo pharmacology

Structural biology Established in 2015

Broad industry experiences

MoA

HTS & novel screening libraries

Assay development

>10 orthogonal biophysical assays for screening & characterization

Close to 200 targets ready for complex structure solution with client ligands

XPRESS, XPEDITE, XPERT services

100s of structures, greater than 15 target classes, small molecules, antibody structures

>80 global partners (pharma, biotech, academic institutes)

Global leader in crystallography & biophysical compound validation

Rapid, high quality protein production

Biophysical assays & screening

Structural biology for difficult targets

FBDD

Global Biology Footprint with Global Centers of Excellence


>250 global collaborators including 14 partners from top 20

pharmaceutical companies

>40 drug candidates delivered in 2008-2014 through

integrated platforms

1st GLP-certified hERG testing; CAP-certified FACS, pathology

and molecular testing Lab (clinical virology)

Snapshot of Capabilities

~340 experienced scientists in in vivo and in vitro biology

13 Senior managers trained in US & Canada, 10 with >15 years

R&D experience

HTS services in US, Europe and China to support global clients

43,000 sq ft biology labs and AAALAC-accredited animal

facility

Partner

R&D Idea

New Target

/Biology

/Mechanism

In Vitro Assay

Development

384 & 1536

Hit Validation

&

Series

Expansion

Hit to Lead

Optimization

Lead

Optimization

to PCC

HTS & Hit

Confirmation

One Stop Shop at WuXi – Integrated Discovery Roadmap

The Only Comprehensive CRO Offers HTS Services in US, EU, & China

US: Assay Design & Screening EU: ProteinChina: Assay Development, Transfer

& Screening

Bio

log

y


Global leader in structural biology and biophysical solutions

Crelux, founded in 2005 at the Innovation & Startup

Center for Biotechnology (IZB) in Martinsried, Germany, is

a global leader in structure-based drug discovery. Crelux

has been providing the drug discovery industry with highly

individualized and efficient solutions to inform and

accelerate their programs for more than a decade. Crelux

provides a number of customized services to support hit-

finding, conformational analysis and lead optimization,

including protein production, biophysical assays,

fragment screening, and X-ray crystallography. The

acquisition represents a further step in the growing

European presence of WuXi AppTec and reaffirms

WuXi's strong commitment to better serving and

interacting with European customers. It provides a

solid foundation for WuXi to expand its integrated

drug discovery services within Europe.

Hit Finding Validation Optimization

High Quality Proteins · FBDD · Biophysical Assays and Screening · X-ray Crystallography

STRUCTURE INFORMED DISCOVERY

Your discovery.

Our solutions.

>10 biophysical validation technologies


of challenging targets

At Europe’s

#1 bio hub

>170 established targets for fast-track complex structures

Delivering Individualized Structure-Based Drug Discovery Solutions


High quality protein production

>10 Orthogonal biophysical assays and screening systems

>170 Targets ready for XPRESS complex structure solution with

client ligands

Fragment-based screening with >3,000-member novel fragment

library

Cryo-EM

Cell-based thermal shift assays (CETSA) for target engagement


>200 New structures every year, across 30 or more protein

targets

Comprehensive coverage of target classes and therapeutic

modalities

Multiple drug discovery programs leading to launched products

supported with Crelux structural biology data

>80% Returning clients


Your world-class partner for accelerated drug discovery

HD Biosciences was founded in 2002 and is

headquartered in Shanghai, China with operating facilities

in Beijing, China and San Diego, USA. As a leading biology

and preclinical service provider, our plate-based

pharmacology, screening capability and AGMTM based

target validation are industry leading platforms with great

reputation. HD Biosciences also provides hit identification,

lead discovery, in vivo pharmacology and other related

services. During the past 14 years, HD Biosciences has

developed into a global company with wide recognition.

The business combination of WuXi AppTec and HD

Biosciences is an important step in strengthening

WuXi’s biology and preclinical service capability from

target validation to lead discovery and optimization,

improving and expanding WuXi’s open-access

enabling service platform. The combination of WuXi

AppTec and HD Biosciences will also provide additional

resources and space to take our biology focused

capabilities to the next level and to speed up the

growth of our business into a leading global player

within our sector. We will provide better services to our

current clients and expand services to WuXi’s global

customers.

Requirements

• Resources & Procurement

• Logistics

• Infrastructure and teams

• Team and specific expertise

• SOP driven process

Gaps &

common

challenges

• Infrastructure gap

• Team & expertise gap

• Technology gap

• Process gap

Shared practice

for solution

development

• Leadership identification & capability assessments, key to the solution

• Resources availability, conventional & alternatives, time line for procurement

• Expertise & infrastructure, internal and external; solutions for in house buildup, backup plan

• Process and PM, faster implementation with open communication & execution

• Mindset for continual improvement

Competitive

advantages at

HD Biosciences

• Talent team with track record

• Experience in running multiple programs & multiple clients

• Established structure with partners and clients in logistics/PM, IT/data support, etc.

• All established SOPs, EHS that compatible with industry standard

Key Elements and Gap Analysis Exercise: When a Collaboration Starts


Plate-based pharmacology with comprehensive assay technologies

and matching screening capability (SAR, HTS, profiling)

Advanced Gene Manipulation (AGMTM) platform featured by

CRISPR, AAV, shRNA for both in vitro and in vivo target validation

Tumor cell panel profiling on 1000+

cell lines supported by

proprietary database with genetic information

State-of-the-art facility with high end instrumentation providing

high throughput solution including RapidFire/ADDA, iQue, Biacore

8k, for bioanalytical and biomarker analysis

Comprehensive animal models covering Oncology, Immuno-

Oncology, Metabolic/liver diseases, and Inflammatory diseases, etc.


Partners with all top 10 world largest pharma and biotech

Great reputation on scientific expertise & value delivery

20 million data points delivered annually from screening center

1,000+ assays developed for hit identification and lead discovery

50+ HTS campaigns launched in the past 3 years

50+ SAR/Hit Triage running in parallel throughout the years

Platforms & Services

to Accelerate

Drug Discovery

Process

Assay & Biology

ADME/SafetyHit to Lead &

Lead Discovery

Efficacy PK/PD Disease

Model

Drug Target

Validation

HD Biosciences Core Competences for Client’s Drug Development R&D

Target ID &

Discovery

Hit ID &

H2L

Lead ID &

Optimization

Safety &

Profiling

Preclinical &

IND


Structural biology case study: in collaboration with a major pharma partner

Objective

An integrated Med. Chem. program to identify a potent and selective inhibitor for epigenetic target.

Biology Achievements

Repeated expression & purification of protein and optimized the purification protocol.

Obtained >120 co-crystal structures with >80% successful rate.

Analyzed co-crystal structures, crystal packing and biological data.

Deployed the structures to design novel targets and improve binding potency (200x), selectivity

(50x), and aqueous solubility.

Co-authors in publication.

Milestones

Demonstrated in vivo efficacy and studies. identified candidates that meet PCC profiles.

Completed in vivo toxicology experiments.

1.1 Å resolution

HCV: discovery of Elbasvir (NS5A inhibitor)

Scope of Partnership

Fully integrated program (Med. Chem., biological testing, DMPK) with WuXi designers.

Results

Key intellectual contributions by WuXi medicinal chemists leading to more than 10 patents

Med. Chem. designed by WuXi chemists

Biology contributed to nomination of 4 preclinical candidates (PCCs) including elbasvir (NCE)

Scientific and Medical Significance

1st Breakthrough Therapy to be designed in “China for the world”

For the patients, significant treatment for hard-to-treat HCV genotypes

Zepatier® : Breakthrough Therapy co-invented through Merck-WuXi partnership

Value to Merck

Full realization of an externalized discovery strategy leading to an approved drug

May 2008program initiation

Nov 2008In vivo PK at WuXi

May 2009

In vitro screens at WuXi

Jan 20101st PCC delivered

MK-4882

Oct 2010

FIH for

MK-4882

Dec 2010

2nd PCC delivered

MK-8742 (elbasvir)

Nov 2011

FIH for

MK-8742

Oct 2013

Breakthrough therapy designation

(elbasvir + grazoprevir)

Jan 2016

US and Canada approved Zepatier®

Computational

Structural

biology,

biology

Medicinal

chemistry

DMPK,

Tox,

process


Documents

Enabling Unbounded Possibilities - RSD